Charter Oak Capital Management’s AstraZeneca AZN Stock Holding History

Charter Oak Capital Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-31	Closed	-$4K	–	222
2022 Q2	$4K	Hold	31	–	–	﹤0.01%	726
2022 Q1	$4K	Buy	31 +30	+3,000%	+$3.6K	﹤0.01%	783
2021 Q4	$0	Sell	1 -75	-99%	-$8.82K	﹤0.01%	850
2021 Q3	$9K	Hold	76	–	–	﹤0.01%	582
2021 Q2	$9K	Hold	76	–	–	﹤0.01%	574
2021 Q1	$8K	Hold	76	–	–	﹤0.01%	567
2020 Q4	$8K	Buy	+76	New	+$8.05K	﹤0.01%	537

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

GQG Partners Ft. Lauderdale, Florida $53.8B AUM 19.23% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

CIBC Private Wealth Group Atlanta, Georgia $59.2B AUM 20.62% 1-Year Est. Return

Charter Oak Capital Management's AZN Position: Q3 2022 in Review

Charter Oak Capital Management sold out of AstraZeneca (AZN) in Q3 2022, closing a stake of 31 shares — an estimated $4K sold.

Charter Oak Capital Management first reported a position in AZN in Q4 2020 and held it in 7 quarters. The position peaked at $9K in Q3 2021. 965 funds tracked by Wall St. Rank hold AZN as of Q3 2022.

Charter Oak Capital Management reported no remaining AstraZeneca position as of Q3 2022 after selling out during the quarter.
Charter Oak Capital Management sold 31 AstraZeneca shares in Q3 2022, an estimated $4K.
Charter Oak Capital Management first reported a position in AstraZeneca in Q4 2020 and held it in 7 quarters.
Charter Oak Capital Management's AstraZeneca position peaked at $9K in Q3 2021.
965 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2022.

Based on Charter Oak Capital Management's 13F filing for Q3 2022, filed 6 Dec 2022.